Experimental Procedures.

Construction and Expression of Mutants -Mutations were introduced into CFTR cDNAs
containing an A52 epitope tag (1) by site-directed mutagenesis as described by Kunkel (2) . A CFTR truncation mutant lacking the NBDs (TMD1+2) consisted of residues 1-388 (TMD1) plus residues 847-1196 (TMD2). The mutant CFTRs were transiently expressed in HEK 293 cells as described previously (3) . HEK 293 cells were transfected with the cDNAs and the medium was changed four hours later to fresh medium (Dulbecco's modified Eagle's medium containing 10% (v/v) calf serum) containing various concentrations of benzbromarone. Cells were harvested 24-40 h after the change in medium. Whole cell extracts of cells (from about 50,000 cells) expressing untagged or A52-tagged CFTRs were subjected to immunoblot analysis using 6.5% (w/v) acrylamide gels and a CFTR polyclonal antibody or monoclonal antibody A52. An equivalent amount of the sample was loaded onto 10% (v/v) SDS-PAGE gels and subjected to immunoblot analysis with a monoclonal antibody against glyceraldehyde-3-phosphate dehydrogenase (GADPH) (internal control). For treatment with endoglycosidase H, a one-tenth volume of 0.5 M sodium citrate, pH 5.5, was added to the solubilized cells followed by addition of 20,000 U/ml endoglycosidase H (New England Biolabs, Mississauga, ON, Canada). The Samples of the reaction mixtures were then subjected to SDS-PAGE (6.5% (w/v) polyacrylamide gels) and immunoblot analysis with a rabbit polyclonal antibody against CFTR (4).
Intramolecular disulfide cross-linking between domains of CFTR can be detected because the cross-linked product migrates with a slower mobility on SDS-PAGE gels (4). Figure S1 . Structure of benzbromarone. Benzbromarone has been used for the treatment of hyperuricemia and gout for about 30 years (5) . A plasma concentration of 0.025 mM benzbromarone could be achieved 2 hours after a single oral dose of 100 mg benzbromarone and the concentration varied depending on the patient's CYP2C9 genotype (5) . Benzbromarone up to 200 mg/day is generally well tolerated with a small number (5-10%) of patients reporting adverse drug reaction such as dizziness and gastrointestinal effects (6) . There have been a few reports of severe toxicity resulting in hepatic failure and the mechanism is likely due to reaction of benzbromarone metabolites with cytochrome CYP2C9 (7). This concern has led to its withdrawal from many markets but it remains available in some European countries as well as in Brazil and Japan. Other derivatives of benzbromarone have been synthesized (8) and may be useful as new therapies for gout and/or cystic fibrosis.
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